Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited. (RLL), was established in the U.S. in 1994. RPI began marketing FDA approved generic products in the U.S. in 1998 after receiving its first FDA approval for Cefaclor, a broad spectrum anti-infective agent.

Ranbaxy Laboratories Inc. (RLI), also a wholly owned subsidiary of Ranbaxy Laboratories Limited. (RLL), is the branded prescription division in the U.S. RLI has been expanding and growing on the strength of Ranbaxy’s R&D efforts, and continuing exploration of novel drug delivery systems (NDDS), licensing activities, mergers and acquisitions. RLI is expanding the visibility and presence of the Ranbaxy name by bringing value-added brand products to the market.

Ranbaxy Pharmaceuticals Inc. and RLI have built on RLL's years of successful pharmaceutical experience and expertise. Ranbaxy has positioned itself as a robust and capable player in the U.S. market through the combined commitment of RPI and RLI to developing new and innovative products and a rapidly expanding generic and brand product portfolio.     Read More >>